High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma

Breast Cancer Research and Treatment

Volumn 89, Issue 1, 2005, Pages 29-34

  Talvensaari Mattila, Anne ^a,b   Turpeenniemi Hujanen, Taina ^a  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Breast cancer; Prognostic factors; Serum TIMP 1

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; BREAST CARCINOMA; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LABORATORY TEST; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FINLAND; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 13644272139     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-1006-8     Document Type: Article

References (28)

1. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991
2. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM: Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 59: 329-341, 1993
3. Liotta LA, Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Semin Cancer Biol 1: 99-106, 1990
4. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y: Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 87: 602-611, 1996
5. Garbett EA, Reed MW, Brown NJ: Proteolysis in breast and colorectal cancer. Br J Cancer 8: 287-293, 1999
6. Garbett EA, Reed MW, Stephenson TJ, Brown NJ: Proteolysis in human breast cancer. J Clin Pathol 53: 99-106, 2000
7. Stephenson BEA, Reed TJ, Brown NJ: Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol 55: 300-304, 2002
8. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein, a marker of aggressiveness in breast carcinoma. Cancer 83: 1153-1162, 1998
9. Hirvonen R, Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) in T1-2N0 breast carcinoma. Breast Cancer Res Treat 77: 85-91, 2003
10. Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 89: 1270-1275, 2003
11. Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, Mavrommatis J, Katsarou S, Davaris P: Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 197: 307-313, 2002
12. Nakopoulou L, Giannopoulou I, Lazaris ACh, Alexandrou P, Tsirmpa I, Markaki S, Panayotopoulou E, Keramopoulos A: The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells. APMIS 111: 1023-1036, 2003
13. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T: Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 186: 51-58, 1998
14. Väisänen A, Kallioinen M, von Dickhoff K, Laatikainen L, Höyhtyä M, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) immunoreactive protein. A new prognostic marker in uveal melanoma? J Pathol 188: 56-62, 1999
15. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Berner A, Bryne M, Reich R: High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 17: 799-808, 1999
16. Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T: Serum matrix metalloproteinase-2, -9 and tissue inhibitors of metalloproteinase-1, -2 in lung cancer - TIMP-1 as a prognostic marker. Anticancer Res 20: 1311-1316, 2000
17. Ylisirniö S, Höyhtyä M, Mäkitaro R, Pääkkö P, Risteli J, Kinnula VL, Turpeenniemi-Hujanen T, Jukkola A: Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 7: 1633-1637, 2001
18. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christe IJ, Hoyer-Hansen G, Brunner N, Stephens RW: Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 80(3-4): 495-503, 1999
19. Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, Brunner N: High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 6: 4292-4299, 2000
20. Scarff RW, Torloni H: Histological Typing of Breast Tumours. WHO, Geneva, 1986
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
22. Mantel N: Evaluation of survival data and two new rank order statistics arising in this consideration. Cancer Chemother Rep 50: 163-170, 1966
23. Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Takemiya S, Yanoma S, Noguchi Y, Takanashi Y: Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma. Br J Surg 88: 1596-1601, 2001
24. McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ: High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast carcinoma. Int J Cancer 84: 44-48, 1999
25. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Sörensen S, Overgaard J, Lilja H, Harris A, Murphy G, Brunner N: Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 8: 156-164, 2002
26. Remacle A, McCarthy K, Noel A, Maguire T, McDermott E, O'Higgis N, Foidart JM, Duffy MJ: High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 20, 89(2): 118-121, 2000
27. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, Noguchi Y: Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer. Cancer Lett. 151(1): 81-86, 2000
28. Susskind H, Hymowitz MH, Lau YH, Atkins HL, Hurewitz AN, Valentine ES, Meek AG, Zucker S: Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys 56(4): 1161-1169, 2003